Overview

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate